nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RALBP1—Doxorubicin—ovarian cancer	0.102	0.245	CbGbCtD
Sorafenib—ABCB1—ovarian cancer	0.0782	1	CbGaD
Sorafenib—ABCG2—Topotecan—ovarian cancer	0.0363	0.0871	CbGbCtD
Sorafenib—ABCC2—Paclitaxel—ovarian cancer	0.0198	0.0477	CbGbCtD
Sorafenib—ABCC2—Carboplatin—ovarian cancer	0.0187	0.0449	CbGbCtD
Sorafenib—ABCG2—Paclitaxel—ovarian cancer	0.0179	0.0431	CbGbCtD
Sorafenib—ABCG2—Carboplatin—ovarian cancer	0.0169	0.0406	CbGbCtD
Sorafenib—ABCC2—Docetaxel—ovarian cancer	0.0144	0.0345	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0133	0.0319	CbGbCtD
Sorafenib—CYP3A7—Paclitaxel—ovarian cancer	0.0133	0.0319	CbGbCtD
Sorafenib—ABCB1—Topotecan—ovarian cancer	0.0131	0.0314	CbGbCtD
Sorafenib—ABCG2—Docetaxel—ovarian cancer	0.013	0.0312	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—ovarian cancer	0.0107	0.0257	CbGbCtD
Sorafenib—CYP3A5—Paclitaxel—ovarian cancer	0.00994	0.0239	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—ovarian cancer	0.00967	0.0232	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—ovarian cancer	0.00958	0.023	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.00958	0.023	CbGbCtD
Sorafenib—CYP2C8—Paclitaxel—ovarian cancer	0.00956	0.023	CbGbCtD
Sorafenib—ABCB1—Vinorelbine—ovarian cancer	0.00921	0.0221	CbGbCtD
Sorafenib—CYP2D6—Vinorelbine—ovarian cancer	0.00868	0.0209	CbGbCtD
Sorafenib—CYP3A4—Topotecan—ovarian cancer	0.00783	0.0188	CbGbCtD
Sorafenib—CYP3A5—Docetaxel—ovarian cancer	0.00719	0.0173	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—ovarian cancer	0.0068	0.0163	CbGbCtD
Sorafenib—CYP2C9—Paclitaxel—ovarian cancer	0.00667	0.016	CbGbCtD
Sorafenib—ABCB1—Paclitaxel—ovarian cancer	0.00647	0.0156	CbGbCtD
Sorafenib—CYP3A4—Vinorelbine—ovarian cancer	0.00552	0.0133	CbGbCtD
Sorafenib—ABCB1—Docetaxel—ovarian cancer	0.00468	0.0112	CbGbCtD
Sorafenib—CYP3A4—Paclitaxel—ovarian cancer	0.00388	0.00932	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—ovarian cancer	0.00349	0.00838	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—ovarian cancer	0.00329	0.0079	CbGbCtD
Sorafenib—CYP3A4—Docetaxel—ovarian cancer	0.0028	0.00674	CbGbCtD
Sorafenib—CYP3A4—Doxorubicin—ovarian cancer	0.00209	0.00502	CbGbCtD
Sorafenib—Regorafenib—ABCB1—ovarian cancer	0.000608	0.558	CrCbGaD
Sorafenib—CDK7—Daunorubicin—Epirubicin—ovarian cancer	0.000557	0.173	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Epirubicin—ovarian cancer	0.000557	0.173	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—ovarian cancer	0.000557	0.173	CbGdCrCtD
Sorafenib—RET—epithelium—ovarian cancer	0.000527	0.00401	CbGeAlD
Sorafenib—MAP3K7—decidua—ovarian cancer	0.000527	0.00401	CbGeAlD
Sorafenib—HIPK3—female gonad—ovarian cancer	0.000523	0.00398	CbGeAlD
Sorafenib—HIPK3—vagina—ovarian cancer	0.00052	0.00396	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—ovarian cancer	0.000516	0.16	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—ovarian cancer	0.000516	0.16	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—ovarian cancer	0.000516	0.16	CbGdCrCtD
Sorafenib—MKNK2—decidua—ovarian cancer	0.000511	0.00389	CbGeAlD
Sorafenib—MKNK1—decidua—ovarian cancer	0.000504	0.00384	CbGeAlD
Sorafenib—MAP3K7—endometrium—ovarian cancer	0.0005	0.00381	CbGeAlD
Sorafenib—MAP2K5—myometrium—ovarian cancer	0.0005	0.00381	CbGeAlD
Sorafenib—KDR—myometrium—ovarian cancer	0.0005	0.00381	CbGeAlD
Sorafenib—EPHA6—testis—ovarian cancer	0.0005	0.0038	CbGeAlD
Sorafenib—RET—decidua—ovarian cancer	0.000498	0.00379	CbGeAlD
Sorafenib—TIE1—female gonad—ovarian cancer	0.000489	0.00372	CbGeAlD
Sorafenib—FLT3—female reproductive system—ovarian cancer	0.000489	0.00372	CbGeAlD
Sorafenib—CSF1R—myometrium—ovarian cancer	0.000488	0.00372	CbGeAlD
Sorafenib—FGFR1—uterus—ovarian cancer	0.000487	0.00371	CbGeAlD
Sorafenib—BRAF—bone marrow—ovarian cancer	0.000486	0.0037	CbGeAlD
Sorafenib—MKNK2—endometrium—ovarian cancer	0.000485	0.00369	CbGeAlD
Sorafenib—RALBP1—uterine cervix—ovarian cancer	0.000484	0.00368	CbGeAlD
Sorafenib—Vismodegib—ABCB1—ovarian cancer	0.000482	0.442	CrCbGaD
Sorafenib—KDR—embryo—ovarian cancer	0.000481	0.00366	CbGeAlD
Sorafenib—MKNK1—endometrium—ovarian cancer	0.000479	0.00364	CbGeAlD
Sorafenib—ZAK—testis—ovarian cancer	0.000474	0.00361	CbGeAlD
Sorafenib—CSF1R—embryo—ovarian cancer	0.00047	0.00357	CbGeAlD
Sorafenib—BRAF—female gonad—ovarian cancer	0.000468	0.00357	CbGeAlD
Sorafenib—BRAF—vagina—ovarian cancer	0.000466	0.00354	CbGeAlD
Sorafenib—FLT1—epithelium—ovarian cancer	0.000464	0.00354	CbGeAlD
Sorafenib—HIPK3—testis—ovarian cancer	0.000464	0.00353	CbGeAlD
Sorafenib—RAF1—epithelium—ovarian cancer	0.000462	0.00351	CbGeAlD
Sorafenib—RALBP1—decidua—ovarian cancer	0.000461	0.00351	CbGeAlD
Sorafenib—FLT3—bone marrow—ovarian cancer	0.000461	0.00351	CbGeAlD
Sorafenib—MAP3K7—uterus—ovarian cancer	0.000461	0.00351	CbGeAlD
Sorafenib—FLT1—uterine cervix—ovarian cancer	0.00046	0.00351	CbGeAlD
Sorafenib—RAF1—uterine cervix—ovarian cancer	0.000458	0.00348	CbGeAlD
Sorafenib—EPHB6—uterine cervix—ovarian cancer	0.000455	0.00346	CbGeAlD
Sorafenib—MAP3K19—testis—ovarian cancer	0.000454	0.00346	CbGeAlD
Sorafenib—MKNK2—gonad—ovarian cancer	0.00045	0.00342	CbGeAlD
Sorafenib—EPHX2—female gonad—ovarian cancer	0.000448	0.00341	CbGeAlD
Sorafenib—MKNK2—uterus—ovarian cancer	0.000447	0.0034	CbGeAlD
Sorafenib—EPHX2—vagina—ovarian cancer	0.000445	0.00339	CbGeAlD
Sorafenib—FLT3—female gonad—ovarian cancer	0.000445	0.00338	CbGeAlD
Sorafenib—MKNK1—gonad—ovarian cancer	0.000444	0.00338	CbGeAlD
Sorafenib—FLT4—female reproductive system—ovarian cancer	0.000444	0.00338	CbGeAlD
Sorafenib—KIT—myometrium—ovarian cancer	0.000443	0.00337	CbGeAlD
Sorafenib—FLT1—decidua—ovarian cancer	0.000439	0.00334	CbGeAlD
Sorafenib—RALBP1—endometrium—ovarian cancer	0.000438	0.00333	CbGeAlD
Sorafenib—RAF1—decidua—ovarian cancer	0.000436	0.00332	CbGeAlD
Sorafenib—STK10—uterine cervix—ovarian cancer	0.000436	0.00332	CbGeAlD
Sorafenib—EPHB6—decidua—ovarian cancer	0.000434	0.0033	CbGeAlD
Sorafenib—TIE1—testis—ovarian cancer	0.000433	0.0033	CbGeAlD
Sorafenib—PDGFRB—myometrium—ovarian cancer	0.000433	0.0033	CbGeAlD
Sorafenib—KIT—embryo—ovarian cancer	0.000426	0.00325	CbGeAlD
Sorafenib—FLT4—bone marrow—ovarian cancer	0.000419	0.00319	CbGeAlD
Sorafenib—FLT1—endometrium—ovarian cancer	0.000416	0.00317	CbGeAlD
Sorafenib—PDGFRB—embryo—ovarian cancer	0.000416	0.00317	CbGeAlD
Sorafenib—BRAF—testis—ovarian cancer	0.000415	0.00316	CbGeAlD
Sorafenib—STK10—decidua—ovarian cancer	0.000415	0.00316	CbGeAlD
Sorafenib—RAF1—endometrium—ovarian cancer	0.000414	0.00315	CbGeAlD
Sorafenib—EPHB6—endometrium—ovarian cancer	0.000412	0.00313	CbGeAlD
Sorafenib—PDGFRA—decidua—ovarian cancer	0.000411	0.00313	CbGeAlD
Sorafenib—MAPK11—lymph node—ovarian cancer	0.000404	0.00307	CbGeAlD
Sorafenib—FLT4—female gonad—ovarian cancer	0.000404	0.00307	CbGeAlD
Sorafenib—RALBP1—uterus—ovarian cancer	0.000403	0.00307	CbGeAlD
Sorafenib—MKNK2—female reproductive system—ovarian cancer	0.000402	0.00306	CbGeAlD
Sorafenib—FGFR1—female gonad—ovarian cancer	0.000398	0.00303	CbGeAlD
Sorafenib—CDK7—lymph node—ovarian cancer	0.000397	0.00302	CbGeAlD
Sorafenib—EPHX2—testis—ovarian cancer	0.000397	0.00302	CbGeAlD
Sorafenib—MKNK1—female reproductive system—ovarian cancer	0.000397	0.00302	CbGeAlD
Sorafenib—FGFR1—vagina—ovarian cancer	0.000396	0.00301	CbGeAlD
Sorafenib—FLT3—testis—ovarian cancer	0.000394	0.003	CbGeAlD
Sorafenib—TAOK2—lymph node—ovarian cancer	0.000394	0.003	CbGeAlD
Sorafenib—KDR—epithelium—ovarian cancer	0.000393	0.00299	CbGeAlD
Sorafenib—MAP3K7—bone marrow—ovarian cancer	0.000391	0.00298	CbGeAlD
Sorafenib—AURKC—lymph node—ovarian cancer	0.000391	0.00298	CbGeAlD
Sorafenib—MAP2K5—uterine cervix—ovarian cancer	0.000389	0.00296	CbGeAlD
Sorafenib—KDR—uterine cervix—ovarian cancer	0.000389	0.00296	CbGeAlD
Sorafenib—FLT1—gonad—ovarian cancer	0.000386	0.00294	CbGeAlD
Sorafenib—RAF1—gonad—ovarian cancer	0.000384	0.00292	CbGeAlD
Sorafenib—FLT1—uterus—ovarian cancer	0.000384	0.00292	CbGeAlD
Sorafenib—RAF1—uterus—ovarian cancer	0.000382	0.0029	CbGeAlD
Sorafenib—CSF1R—uterine cervix—ovarian cancer	0.00038	0.00289	CbGeAlD
Sorafenib—MKNK2—bone marrow—ovarian cancer	0.000379	0.00289	CbGeAlD
Sorafenib—MAP3K7—female gonad—ovarian cancer	0.000377	0.00287	CbGeAlD
Sorafenib—MAP3K7—vagina—ovarian cancer	0.000375	0.00285	CbGeAlD
Sorafenib—MKNK1—bone marrow—ovarian cancer	0.000374	0.00285	CbGeAlD
Sorafenib—MAP2K5—decidua—ovarian cancer	0.000371	0.00282	CbGeAlD
Sorafenib—KDR—decidua—ovarian cancer	0.000371	0.00282	CbGeAlD
Sorafenib—STK10—gonad—ovarian cancer	0.000366	0.00278	CbGeAlD
Sorafenib—MKNK2—female gonad—ovarian cancer	0.000365	0.00278	CbGeAlD
Sorafenib—STK10—uterus—ovarian cancer	0.000363	0.00277	CbGeAlD
Sorafenib—MKNK2—vagina—ovarian cancer	0.000363	0.00277	CbGeAlD
Sorafenib—RALBP1—female reproductive system—ovarian cancer	0.000363	0.00276	CbGeAlD
Sorafenib—PDGFRA—gonad—ovarian cancer	0.000362	0.00276	CbGeAlD
Sorafenib—CSF1R—decidua—ovarian cancer	0.000362	0.00275	CbGeAlD
Sorafenib—MKNK1—female gonad—ovarian cancer	0.000361	0.00275	CbGeAlD
Sorafenib—PDGFRA—uterus—ovarian cancer	0.00036	0.00274	CbGeAlD
Sorafenib—MKNK1—vagina—ovarian cancer	0.000359	0.00273	CbGeAlD
Sorafenib—FLT4—testis—ovarian cancer	0.000358	0.00273	CbGeAlD
Sorafenib—FGFR1—testis—ovarian cancer	0.000353	0.00269	CbGeAlD
Sorafenib—MAP2K5—endometrium—ovarian cancer	0.000352	0.00268	CbGeAlD
Sorafenib—KDR—endometrium—ovarian cancer	0.000352	0.00268	CbGeAlD
Sorafenib—KIT—epithelium—ovarian cancer	0.000348	0.00265	CbGeAlD
Sorafenib—FLT1—female reproductive system—ovarian cancer	0.000345	0.00263	CbGeAlD
Sorafenib—KIT—uterine cervix—ovarian cancer	0.000345	0.00263	CbGeAlD
Sorafenib—CSF1R—endometrium—ovarian cancer	0.000344	0.00262	CbGeAlD
Sorafenib—ZAK—lymph node—ovarian cancer	0.000343	0.00261	CbGeAlD
Sorafenib—RAF1—female reproductive system—ovarian cancer	0.000343	0.00261	CbGeAlD
Sorafenib—HTR2B—myometrium—ovarian cancer	0.000343	0.00261	CbGeAlD
Sorafenib—RALBP1—bone marrow—ovarian cancer	0.000342	0.00261	CbGeAlD
Sorafenib—PDGFRB—epithelium—ovarian cancer	0.00034	0.00259	CbGeAlD
Sorafenib—PDGFRB—uterine cervix—ovarian cancer	0.000337	0.00256	CbGeAlD
Sorafenib—HIPK3—lymph node—ovarian cancer	0.000336	0.00256	CbGeAlD
Sorafenib—MAP3K7—testis—ovarian cancer	0.000334	0.00255	CbGeAlD
Sorafenib—RALBP1—female gonad—ovarian cancer	0.00033	0.00251	CbGeAlD
Sorafenib—KIT—decidua—ovarian cancer	0.000329	0.0025	CbGeAlD
Sorafenib—RALBP1—vagina—ovarian cancer	0.000328	0.0025	CbGeAlD
Sorafenib—STK10—female reproductive system—ovarian cancer	0.000327	0.00249	CbGeAlD
Sorafenib—KDR—uterus—ovarian cancer	0.000324	0.00247	CbGeAlD
Sorafenib—MKNK2—testis—ovarian cancer	0.000324	0.00247	CbGeAlD
Sorafenib—RAF1—bone marrow—ovarian cancer	0.000324	0.00246	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—ovarian cancer	0.000323	0.00246	CbGeAlD
Sorafenib—PDGFRB—decidua—ovarian cancer	0.000321	0.00244	CbGeAlD
Sorafenib—MKNK1—testis—ovarian cancer	0.00032	0.00244	CbGeAlD
Sorafenib—CSF1R—gonad—ovarian cancer	0.000319	0.00243	CbGeAlD
Sorafenib—CSF1R—uterus—ovarian cancer	0.000317	0.00241	CbGeAlD
Sorafenib—RET—testis—ovarian cancer	0.000316	0.00241	CbGeAlD
Sorafenib—TIE1—lymph node—ovarian cancer	0.000314	0.00239	CbGeAlD
Sorafenib—FLT1—female gonad—ovarian cancer	0.000314	0.00239	CbGeAlD
Sorafenib—RAF1—female gonad—ovarian cancer	0.000312	0.00238	CbGeAlD
Sorafenib—FLT1—vagina—ovarian cancer	0.000312	0.00238	CbGeAlD
Sorafenib—KIT—endometrium—ovarian cancer	0.000312	0.00237	CbGeAlD
Sorafenib—EPHB6—female gonad—ovarian cancer	0.00031	0.00236	CbGeAlD
Sorafenib—RAF1—vagina—ovarian cancer	0.00031	0.00236	CbGeAlD
Sorafenib—EPHB6—vagina—ovarian cancer	0.000308	0.00235	CbGeAlD
Sorafenib—STK10—bone marrow—ovarian cancer	0.000308	0.00235	CbGeAlD
Sorafenib—PDGFRB—endometrium—ovarian cancer	0.000305	0.00232	CbGeAlD
Sorafenib—BRAF—lymph node—ovarian cancer	0.000301	0.00229	CbGeAlD
Sorafenib—STK10—female gonad—ovarian cancer	0.000297	0.00226	CbGeAlD
Sorafenib—STK10—vagina—ovarian cancer	0.000295	0.00225	CbGeAlD
Sorafenib—PDGFRA—female gonad—ovarian cancer	0.000294	0.00224	CbGeAlD
Sorafenib—RALBP1—testis—ovarian cancer	0.000293	0.00223	CbGeAlD
Sorafenib—PDGFRA—vagina—ovarian cancer	0.000292	0.00223	CbGeAlD
Sorafenib—KDR—female reproductive system—ovarian cancer	0.000292	0.00222	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—ovarian cancer	0.000292	0.00222	CbGeAlD
Sorafenib—KIT—gonad—ovarian cancer	0.000289	0.0022	CbGeAlD
Sorafenib—EPHX2—lymph node—ovarian cancer	0.000288	0.00219	CbGeAlD
Sorafenib—KIT—uterus—ovarian cancer	0.000287	0.00219	CbGeAlD
Sorafenib—FLT3—lymph node—ovarian cancer	0.000286	0.00218	CbGeAlD
Sorafenib—CSF1R—female reproductive system—ovarian cancer	0.000285	0.00217	CbGeAlD
Sorafenib—PDGFRB—gonad—ovarian cancer	0.000283	0.00215	CbGeAlD
Sorafenib—PDGFRB—uterus—ovarian cancer	0.000281	0.00214	CbGeAlD
Sorafenib—FLT1—testis—ovarian cancer	0.000278	0.00212	CbGeAlD
Sorafenib—RAF1—testis—ovarian cancer	0.000277	0.00211	CbGeAlD
Sorafenib—KDR—bone marrow—ovarian cancer	0.000275	0.0021	CbGeAlD
Sorafenib—EPHB6—testis—ovarian cancer	0.000275	0.00209	CbGeAlD
Sorafenib—CSF1R—bone marrow—ovarian cancer	0.000269	0.00205	CbGeAlD
Sorafenib—HTR2B—uterine cervix—ovarian cancer	0.000267	0.00203	CbGeAlD
Sorafenib—MAP2K5—female gonad—ovarian cancer	0.000265	0.00202	CbGeAlD
Sorafenib—KDR—female gonad—ovarian cancer	0.000265	0.00202	CbGeAlD
Sorafenib—KDR—vagina—ovarian cancer	0.000264	0.00201	CbGeAlD
Sorafenib—MAP2K5—vagina—ovarian cancer	0.000264	0.00201	CbGeAlD
Sorafenib—STK10—testis—ovarian cancer	0.000264	0.00201	CbGeAlD
Sorafenib—PDGFRA—testis—ovarian cancer	0.000261	0.00199	CbGeAlD
Sorafenib—FLT4—lymph node—ovarian cancer	0.00026	0.00198	CbGeAlD
Sorafenib—CSF1R—female gonad—ovarian cancer	0.000259	0.00197	CbGeAlD
Sorafenib—KIT—female reproductive system—ovarian cancer	0.000258	0.00197	CbGeAlD
Sorafenib—CSF1R—vagina—ovarian cancer	0.000257	0.00196	CbGeAlD
Sorafenib—FGFR1—lymph node—ovarian cancer	0.000256	0.00195	CbGeAlD
Sorafenib—HTR2B—decidua—ovarian cancer	0.000254	0.00194	CbGeAlD
Sorafenib—PDGFRB—female reproductive system—ovarian cancer	0.000252	0.00192	CbGeAlD
Sorafenib—KIT—bone marrow—ovarian cancer	0.000244	0.00186	CbGeAlD
Sorafenib—ABCG2—myometrium—ovarian cancer	0.000243	0.00185	CbGeAlD
Sorafenib—MAP3K7—lymph node—ovarian cancer	0.000242	0.00185	CbGeAlD
Sorafenib—HTR2B—endometrium—ovarian cancer	0.000241	0.00184	CbGeAlD
Sorafenib—PDGFRB—bone marrow—ovarian cancer	0.000238	0.00181	CbGeAlD
Sorafenib—KDR—testis—ovarian cancer	0.000235	0.00179	CbGeAlD
Sorafenib—MAP2K5—testis—ovarian cancer	0.000235	0.00179	CbGeAlD
Sorafenib—KIT—female gonad—ovarian cancer	0.000235	0.00179	CbGeAlD
Sorafenib—MKNK2—lymph node—ovarian cancer	0.000235	0.00179	CbGeAlD
Sorafenib—KIT—vagina—ovarian cancer	0.000234	0.00178	CbGeAlD
Sorafenib—MKNK1—lymph node—ovarian cancer	0.000232	0.00177	CbGeAlD
Sorafenib—CSF1R—testis—ovarian cancer	0.00023	0.00175	CbGeAlD
Sorafenib—PDGFRB—female gonad—ovarian cancer	0.00023	0.00175	CbGeAlD
Sorafenib—RET—lymph node—ovarian cancer	0.000229	0.00174	CbGeAlD
Sorafenib—PDGFRB—vagina—ovarian cancer	0.000228	0.00174	CbGeAlD
Sorafenib—ABCC4—uterus—ovarian cancer	0.000224	0.0017	CbGeAlD
Sorafenib—HTR2B—uterus—ovarian cancer	0.000222	0.00169	CbGeAlD
Sorafenib—HTR2C—female reproductive system—ovarian cancer	0.000213	0.00162	CbGeAlD
Sorafenib—RALBP1—lymph node—ovarian cancer	0.000212	0.00162	CbGeAlD
Sorafenib—KIT—testis—ovarian cancer	0.000209	0.00159	CbGeAlD
Sorafenib—PDGFRB—testis—ovarian cancer	0.000204	0.00155	CbGeAlD
Sorafenib—FLT1—lymph node—ovarian cancer	0.000202	0.00154	CbGeAlD
Sorafenib—ABCC4—female reproductive system—ovarian cancer	0.000201	0.00153	CbGeAlD
Sorafenib—RAF1—lymph node—ovarian cancer	0.000201	0.00153	CbGeAlD
Sorafenib—HTR2B—female reproductive system—ovarian cancer	0.0002	0.00152	CbGeAlD
Sorafenib—EPHB6—lymph node—ovarian cancer	0.000199	0.00152	CbGeAlD
Sorafenib—ABCC2—female reproductive system—ovarian cancer	0.000195	0.00148	CbGeAlD
Sorafenib—STK10—lymph node—ovarian cancer	0.000191	0.00145	CbGeAlD
Sorafenib—ABCC4—bone marrow—ovarian cancer	0.00019	0.00144	CbGeAlD
Sorafenib—ABCG2—uterine cervix—ovarian cancer	0.000189	0.00144	CbGeAlD
Sorafenib—PDGFRA—lymph node—ovarian cancer	0.000189	0.00144	CbGeAlD
Sorafenib—ABCC4—female gonad—ovarian cancer	0.000183	0.00139	CbGeAlD
Sorafenib—HTR2B—vagina—ovarian cancer	0.000181	0.00138	CbGeAlD
Sorafenib—ABCG2—decidua—ovarian cancer	0.00018	0.00137	CbGeAlD
Sorafenib—CYP2C8—endometrium—ovarian cancer	0.000176	0.00134	CbGeAlD
Sorafenib—CYP3A5—uterine cervix—ovarian cancer	0.000176	0.00134	CbGeAlD
Sorafenib—ABCG2—endometrium—ovarian cancer	0.000171	0.0013	CbGeAlD
Sorafenib—KDR—lymph node—ovarian cancer	0.000171	0.0013	CbGeAlD
Sorafenib—MAP2K5—lymph node—ovarian cancer	0.000171	0.0013	CbGeAlD
Sorafenib—CSF1R—lymph node—ovarian cancer	0.000166	0.00127	CbGeAlD
Sorafenib—ABCC4—testis—ovarian cancer	0.000162	0.00123	CbGeAlD
Sorafenib—ABCG2—uterus—ovarian cancer	0.000158	0.0012	CbGeAlD
Sorafenib—ABCC2—testis—ovarian cancer	0.000157	0.0012	CbGeAlD
Sorafenib—CYP2C19—vagina—ovarian cancer	0.000151	0.00115	CbGeAlD
Sorafenib—KIT—lymph node—ovarian cancer	0.000151	0.00115	CbGeAlD
Sorafenib—PDGFRB—lymph node—ovarian cancer	0.000148	0.00112	CbGeAlD
Sorafenib—CYP2B6—gonad—ovarian cancer	0.000147	0.00112	CbGeAlD
Sorafenib—CYP2C8—female reproductive system—ovarian cancer	0.000146	0.00111	CbGeAlD
Sorafenib—ABCG2—bone marrow—ovarian cancer	0.000134	0.00102	CbGeAlD
Sorafenib—CYP2C8—vagina—ovarian cancer	0.000132	0.001	CbGeAlD
Sorafenib—CYP2B6—female reproductive system—ovarian cancer	0.000131	0.000996	CbGeAlD
Sorafenib—CYP2C9—female reproductive system—ovarian cancer	0.00013	0.000987	CbGeAlD
Sorafenib—ABCG2—female gonad—ovarian cancer	0.000129	0.000983	CbGeAlD
Sorafenib—ABCG2—vagina—ovarian cancer	0.000128	0.000977	CbGeAlD
Sorafenib—ABCB1—myometrium—ovarian cancer	0.00012	0.000913	CbGeAlD
Sorafenib—CYP3A5—female gonad—ovarian cancer	0.00012	0.000912	CbGeAlD
Sorafenib—CYP3A5—vagina—ovarian cancer	0.000119	0.000907	CbGeAlD
Sorafenib—CYP2B6—vagina—ovarian cancer	0.000118	0.000901	CbGeAlD
Sorafenib—CYP2C8—testis—ovarian cancer	0.000118	0.000896	CbGeAlD
Sorafenib—ABCC4—lymph node—ovarian cancer	0.000118	0.000895	CbGeAlD
Sorafenib—HTR2B—lymph node—ovarian cancer	0.000117	0.00089	CbGeAlD
Sorafenib—ABCB1—embryo—ovarian cancer	0.000115	0.000879	CbGeAlD
Sorafenib—ABCG2—testis—ovarian cancer	0.000114	0.000872	CbGeAlD
Sorafenib—ABCC2—lymph node—ovarian cancer	0.000114	0.000866	CbGeAlD
Sorafenib—CYP2B6—testis—ovarian cancer	0.000106	0.000804	CbGeAlD
Sorafenib—Hypokalaemia—Epirubicin—ovarian cancer	0.000105	0.000581	CcSEcCtD
Sorafenib—Hypertension—Paclitaxel—ovarian cancer	0.000105	0.00058	CcSEcCtD
Sorafenib—Alopecia—Docetaxel—ovarian cancer	0.000104	0.000578	CcSEcCtD
Sorafenib—Pruritus—Vinorelbine—ovarian cancer	0.000104	0.000577	CcSEcCtD
Sorafenib—Breast disorder—Epirubicin—ovarian cancer	0.000104	0.000577	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000104	0.000575	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000104	0.000575	CcSEcCtD
Sorafenib—Mental disorder—Docetaxel—ovarian cancer	0.000103	0.000573	CcSEcCtD
Sorafenib—Myalgia—Paclitaxel—ovarian cancer	0.000103	0.000572	CcSEcCtD
Sorafenib—Arthralgia—Paclitaxel—ovarian cancer	0.000103	0.000572	CcSEcCtD
Sorafenib—Nasopharyngitis—Epirubicin—ovarian cancer	0.000103	0.000571	CcSEcCtD
Sorafenib—Malnutrition—Docetaxel—ovarian cancer	0.000103	0.00057	CcSEcCtD
Sorafenib—Erythema—Docetaxel—ovarian cancer	0.000103	0.00057	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000102	0.000568	CcSEcCtD
Sorafenib—Nausea—Topotecan—ovarian cancer	0.000102	0.000566	CcSEcCtD
Sorafenib—Gastritis—Epirubicin—ovarian cancer	0.000102	0.000565	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000101	0.000563	CcSEcCtD
Sorafenib—Dry mouth—Paclitaxel—ovarian cancer	0.000101	0.00056	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—ovarian cancer	0.000101	0.000559	CcSEcCtD
Sorafenib—Diarrhoea—Vinorelbine—ovarian cancer	0.000101	0.000558	CcSEcCtD
Sorafenib—Dysgeusia—Docetaxel—ovarian cancer	0.000101	0.000558	CcSEcCtD
Sorafenib—Nausea—Melphalan—ovarian cancer	9.99e-05	0.000555	CcSEcCtD
Sorafenib—Dysphagia—Epirubicin—ovarian cancer	9.94e-05	0.000552	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—ovarian cancer	9.89e-05	0.000549	CcSEcCtD
Sorafenib—Anaphylactic shock—Paclitaxel—ovarian cancer	9.89e-05	0.000549	CcSEcCtD
Sorafenib—CYP3A4—female reproductive system—ovarian cancer	9.88e-05	0.000752	CbGeAlD
Sorafenib—Muscle spasms—Docetaxel—ovarian cancer	9.87e-05	0.000548	CcSEcCtD
Sorafenib—Infection—Paclitaxel—ovarian cancer	9.82e-05	0.000545	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—ovarian cancer	9.75e-05	0.000541	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—ovarian cancer	9.74e-05	0.000541	CcSEcCtD
Sorafenib—Shock—Paclitaxel—ovarian cancer	9.73e-05	0.00054	CcSEcCtD
Sorafenib—CYP2D6—female reproductive system—ovarian cancer	9.73e-05	0.00074	CbGeAlD
Sorafenib—Dizziness—Vinorelbine—ovarian cancer	9.72e-05	0.000539	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—ovarian cancer	9.72e-05	0.000539	CcSEcCtD
Sorafenib—Nervous system disorder—Paclitaxel—ovarian cancer	9.69e-05	0.000538	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—ovarian cancer	9.68e-05	0.000537	CcSEcCtD
Sorafenib—Thrombocytopenia—Paclitaxel—ovarian cancer	9.68e-05	0.000537	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—ovarian cancer	9.61e-05	0.000534	CcSEcCtD
Sorafenib—Skin disorder—Paclitaxel—ovarian cancer	9.6e-05	0.000533	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	9.58e-05	0.000532	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	9.58e-05	0.000532	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—ovarian cancer	9.51e-05	0.000528	CcSEcCtD
Sorafenib—Anaemia—Docetaxel—ovarian cancer	9.49e-05	0.000527	CcSEcCtD
Sorafenib—Anorexia—Paclitaxel—ovarian cancer	9.42e-05	0.000523	CcSEcCtD
Sorafenib—ABCB1—epithelium—ovarian cancer	9.42e-05	0.000717	CbGeAlD
Sorafenib—Gastritis—Doxorubicin—ovarian cancer	9.42e-05	0.000523	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	9.38e-05	0.000521	CcSEcCtD
Sorafenib—Vomiting—Vinorelbine—ovarian cancer	9.34e-05	0.000519	CcSEcCtD
Sorafenib—ABCB1—uterine cervix—ovarian cancer	9.34e-05	0.000711	CbGeAlD
Sorafenib—Neutropenia—Epirubicin—ovarian cancer	9.29e-05	0.000516	CcSEcCtD
Sorafenib—Rash—Vinorelbine—ovarian cancer	9.27e-05	0.000514	CcSEcCtD
Sorafenib—Dermatitis—Vinorelbine—ovarian cancer	9.26e-05	0.000514	CcSEcCtD
Sorafenib—Headache—Vinorelbine—ovarian cancer	9.21e-05	0.000511	CcSEcCtD
Sorafenib—Syncope—Docetaxel—ovarian cancer	9.21e-05	0.000511	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—ovarian cancer	9.2e-05	0.00051	CcSEcCtD
Sorafenib—Leukopenia—Docetaxel—ovarian cancer	9.19e-05	0.00051	CcSEcCtD
Sorafenib—Loss of consciousness—Docetaxel—ovarian cancer	9.02e-05	0.000501	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—ovarian cancer	9.02e-05	0.0005	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	9.01e-05	0.0005	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—ovarian cancer	8.99e-05	0.000499	CcSEcCtD
Sorafenib—Cough—Docetaxel—ovarian cancer	8.96e-05	0.000497	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—ovarian cancer	8.91e-05	0.000495	CcSEcCtD
Sorafenib—ABCB1—decidua—ovarian cancer	8.9e-05	0.000677	CbGeAlD
Sorafenib—Hypertension—Docetaxel—ovarian cancer	8.86e-05	0.000492	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—ovarian cancer	8.86e-05	0.000492	CcSEcCtD
Sorafenib—Infestation—Epirubicin—ovarian cancer	8.86e-05	0.000492	CcSEcCtD
Sorafenib—CYP2D6—female gonad—ovarian cancer	8.85e-05	0.000674	CbGeAlD
Sorafenib—Dyspnoea—Paclitaxel—ovarian cancer	8.81e-05	0.000489	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	8.79e-05	0.000488	CcSEcCtD
Sorafenib—Myalgia—Docetaxel—ovarian cancer	8.74e-05	0.000485	CcSEcCtD
Sorafenib—Arthralgia—Docetaxel—ovarian cancer	8.74e-05	0.000485	CcSEcCtD
Sorafenib—Nausea—Vinorelbine—ovarian cancer	8.73e-05	0.000485	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—ovarian cancer	8.71e-05	0.000483	CcSEcCtD
Sorafenib—Dyspepsia—Paclitaxel—ovarian cancer	8.7e-05	0.000483	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—ovarian cancer	8.69e-05	0.000482	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	8.68e-05	0.000482	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—ovarian cancer	8.64e-05	0.000479	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—ovarian cancer	8.64e-05	0.000479	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—ovarian cancer	8.6e-05	0.000477	CcSEcCtD
Sorafenib—Decreased appetite—Paclitaxel—ovarian cancer	8.59e-05	0.000477	CcSEcCtD
Sorafenib—Dry mouth—Docetaxel—ovarian cancer	8.55e-05	0.000474	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	8.53e-05	0.000474	CcSEcCtD
Sorafenib—Fatigue—Paclitaxel—ovarian cancer	8.52e-05	0.000473	CcSEcCtD
Sorafenib—Constipation—Paclitaxel—ovarian cancer	8.45e-05	0.000469	CcSEcCtD
Sorafenib—Pain—Paclitaxel—ovarian cancer	8.45e-05	0.000469	CcSEcCtD
Sorafenib—ABCB1—endometrium—ovarian cancer	8.45e-05	0.000643	CbGeAlD
Sorafenib—Hepatobiliary disease—Epirubicin—ovarian cancer	8.38e-05	0.000465	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—ovarian cancer	8.38e-05	0.000465	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—ovarian cancer	8.36e-05	0.000464	CcSEcCtD
Sorafenib—Infection—Docetaxel—ovarian cancer	8.32e-05	0.000462	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—ovarian cancer	8.32e-05	0.000462	CcSEcCtD
Sorafenib—ABCG2—lymph node—ovarian cancer	8.3e-05	0.000632	CbGeAlD
Sorafenib—Pneumonia—Doxorubicin—ovarian cancer	8.25e-05	0.000458	CcSEcCtD
Sorafenib—Shock—Docetaxel—ovarian cancer	8.24e-05	0.000458	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—ovarian cancer	8.22e-05	0.000456	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—ovarian cancer	8.2e-05	0.000455	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—ovarian cancer	8.2e-05	0.000455	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—ovarian cancer	8.2e-05	0.000455	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—ovarian cancer	8.14e-05	0.000452	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	8.13e-05	0.000451	CcSEcCtD
Sorafenib—Gastrointestinal pain—Paclitaxel—ovarian cancer	8.08e-05	0.000449	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—ovarian cancer	8.06e-05	0.000447	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.04e-05	0.000446	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—ovarian cancer	8e-05	0.000444	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—ovarian cancer	7.99e-05	0.000444	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—ovarian cancer	7.99e-05	0.000444	CcSEcCtD
Sorafenib—Anorexia—Docetaxel—ovarian cancer	7.99e-05	0.000443	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—ovarian cancer	7.95e-05	0.000441	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—ovarian cancer	7.86e-05	0.000436	CcSEcCtD
Sorafenib—Urticaria—Paclitaxel—ovarian cancer	7.85e-05	0.000436	CcSEcCtD
Sorafenib—CYP2D6—testis—ovarian cancer	7.85e-05	0.000597	CbGeAlD
Sorafenib—ABCB1—gonad—ovarian cancer	7.83e-05	0.000596	CbGeAlD
Sorafenib—Connective tissue disorder—Epirubicin—ovarian cancer	7.82e-05	0.000434	CcSEcCtD
Sorafenib—Body temperature increased—Paclitaxel—ovarian cancer	7.81e-05	0.000434	CcSEcCtD
Sorafenib—Abdominal pain—Paclitaxel—ovarian cancer	7.81e-05	0.000434	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—ovarian cancer	7.8e-05	0.000433	CcSEcCtD
Sorafenib—ABCB1—uterus—ovarian cancer	7.78e-05	0.000592	CbGeAlD
Sorafenib—Hepatobiliary disease—Doxorubicin—ovarian cancer	7.75e-05	0.00043	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—ovarian cancer	7.73e-05	0.000429	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.63e-05	0.000424	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—ovarian cancer	7.52e-05	0.000417	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—ovarian cancer	7.47e-05	0.000415	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—ovarian cancer	7.42e-05	0.000412	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—ovarian cancer	7.4e-05	0.000411	CcSEcCtD
Sorafenib—Flushing—Epirubicin—ovarian cancer	7.38e-05	0.00041	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—ovarian cancer	7.38e-05	0.00041	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—ovarian cancer	7.38e-05	0.000409	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—ovarian cancer	7.36e-05	0.000409	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—ovarian cancer	7.28e-05	0.000404	CcSEcCtD
Sorafenib—Hypersensitivity—Paclitaxel—ovarian cancer	7.28e-05	0.000404	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—ovarian cancer	7.27e-05	0.000403	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.23e-05	0.000401	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—ovarian cancer	7.23e-05	0.000401	CcSEcCtD
Sorafenib—Fatigue—Docetaxel—ovarian cancer	7.22e-05	0.000401	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—ovarian cancer	7.22e-05	0.000401	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—ovarian cancer	7.22e-05	0.0004	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—ovarian cancer	7.19e-05	0.000399	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—ovarian cancer	7.17e-05	0.000398	CcSEcCtD
Sorafenib—Constipation—Docetaxel—ovarian cancer	7.17e-05	0.000398	CcSEcCtD
Sorafenib—Pain—Docetaxel—ovarian cancer	7.17e-05	0.000398	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—ovarian cancer	7.11e-05	0.000394	CcSEcCtD
Sorafenib—Asthenia—Paclitaxel—ovarian cancer	7.09e-05	0.000394	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—ovarian cancer	7.03e-05	0.00039	CcSEcCtD
Sorafenib—ABCB1—female reproductive system—ovarian cancer	7e-05	0.000533	CbGeAlD
Sorafenib—Pruritus—Paclitaxel—ovarian cancer	6.99e-05	0.000388	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—ovarian cancer	6.97e-05	0.000387	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—ovarian cancer	6.96e-05	0.000386	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—ovarian cancer	6.92e-05	0.000384	CcSEcCtD
Sorafenib—Erythema—Epirubicin—ovarian cancer	6.92e-05	0.000384	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—ovarian cancer	6.86e-05	0.000381	CcSEcCtD
Sorafenib—Gastrointestinal pain—Docetaxel—ovarian cancer	6.85e-05	0.00038	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—ovarian cancer	6.83e-05	0.000379	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—ovarian cancer	6.83e-05	0.000379	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—ovarian cancer	6.78e-05	0.000376	CcSEcCtD
Sorafenib—Diarrhoea—Paclitaxel—ovarian cancer	6.76e-05	0.000375	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—ovarian cancer	6.68e-05	0.000371	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—ovarian cancer	6.66e-05	0.00037	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—ovarian cancer	6.65e-05	0.000369	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—ovarian cancer	6.63e-05	0.000368	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—ovarian cancer	6.62e-05	0.000368	CcSEcCtD
Sorafenib—Body temperature increased—Docetaxel—ovarian cancer	6.62e-05	0.000368	CcSEcCtD
Sorafenib—ABCB1—bone marrow—ovarian cancer	6.6e-05	0.000503	CbGeAlD
Sorafenib—Arrhythmia—Doxorubicin—ovarian cancer	6.58e-05	0.000365	CcSEcCtD
Sorafenib—Dizziness—Paclitaxel—ovarian cancer	6.54e-05	0.000363	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—ovarian cancer	6.5e-05	0.000361	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—ovarian cancer	6.45e-05	0.000358	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—ovarian cancer	6.41e-05	0.000356	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—ovarian cancer	6.41e-05	0.000356	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—ovarian cancer	6.4e-05	0.000355	CcSEcCtD
Sorafenib—ABCB1—female gonad—ovarian cancer	6.37e-05	0.000485	CbGeAlD
Sorafenib—ABCB1—vagina—ovarian cancer	6.33e-05	0.000482	CbGeAlD
Sorafenib—Vomiting—Paclitaxel—ovarian cancer	6.29e-05	0.000349	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—ovarian cancer	6.27e-05	0.000348	CcSEcCtD
Sorafenib—Rash—Paclitaxel—ovarian cancer	6.23e-05	0.000346	CcSEcCtD
Sorafenib—Dermatitis—Paclitaxel—ovarian cancer	6.23e-05	0.000346	CcSEcCtD
Sorafenib—Syncope—Epirubicin—ovarian cancer	6.21e-05	0.000345	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—ovarian cancer	6.2e-05	0.000344	CcSEcCtD
Sorafenib—Headache—Paclitaxel—ovarian cancer	6.19e-05	0.000344	CcSEcCtD
Sorafenib—Hypersensitivity—Docetaxel—ovarian cancer	6.17e-05	0.000343	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—ovarian cancer	6.16e-05	0.000342	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—ovarian cancer	6.09e-05	0.000338	CcSEcCtD
Sorafenib—Cough—Epirubicin—ovarian cancer	6.04e-05	0.000335	CcSEcCtD
Sorafenib—Asthenia—Docetaxel—ovarian cancer	6.01e-05	0.000334	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—ovarian cancer	5.98e-05	0.000332	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—ovarian cancer	5.93e-05	0.000329	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—ovarian cancer	5.92e-05	0.000329	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—ovarian cancer	5.9e-05	0.000327	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—ovarian cancer	5.9e-05	0.000327	CcSEcCtD
Sorafenib—Nausea—Paclitaxel—ovarian cancer	5.87e-05	0.000326	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.85e-05	0.000325	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—ovarian cancer	5.77e-05	0.00032	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—ovarian cancer	5.75e-05	0.000319	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—ovarian cancer	5.74e-05	0.000318	CcSEcCtD
Sorafenib—Diarrhoea—Docetaxel—ovarian cancer	5.73e-05	0.000318	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—ovarian cancer	5.65e-05	0.000314	CcSEcCtD
Sorafenib—ABCB1—testis—ovarian cancer	5.65e-05	0.00043	CbGeAlD
Sorafenib—Loss of consciousness—Doxorubicin—ovarian cancer	5.63e-05	0.000313	CcSEcCtD
Sorafenib—Infection—Epirubicin—ovarian cancer	5.61e-05	0.000312	CcSEcCtD
Sorafenib—Cough—Doxorubicin—ovarian cancer	5.59e-05	0.00031	CcSEcCtD
Sorafenib—Shock—Epirubicin—ovarian cancer	5.56e-05	0.000309	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—ovarian cancer	5.54e-05	0.000308	CcSEcCtD
Sorafenib—Dizziness—Docetaxel—ovarian cancer	5.54e-05	0.000308	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—ovarian cancer	5.53e-05	0.000307	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—ovarian cancer	5.53e-05	0.000307	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—ovarian cancer	5.49e-05	0.000305	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—ovarian cancer	5.45e-05	0.000303	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—ovarian cancer	5.45e-05	0.000303	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.42e-05	0.000301	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—ovarian cancer	5.39e-05	0.000299	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—ovarian cancer	5.33e-05	0.000296	CcSEcCtD
Sorafenib—Vomiting—Docetaxel—ovarian cancer	5.33e-05	0.000296	CcSEcCtD
Sorafenib—Rash—Docetaxel—ovarian cancer	5.28e-05	0.000293	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—ovarian cancer	5.28e-05	0.000293	CcSEcCtD
Sorafenib—Headache—Docetaxel—ovarian cancer	5.25e-05	0.000291	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—ovarian cancer	5.23e-05	0.00029	CcSEcCtD
Sorafenib—Infection—Doxorubicin—ovarian cancer	5.2e-05	0.000288	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.15e-05	0.000286	CcSEcCtD
Sorafenib—Shock—Doxorubicin—ovarian cancer	5.14e-05	0.000286	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—ovarian cancer	5.13e-05	0.000285	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—ovarian cancer	5.12e-05	0.000284	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—ovarian cancer	5.08e-05	0.000282	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—ovarian cancer	5.04e-05	0.00028	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—ovarian cancer	4.98e-05	0.000277	CcSEcCtD
Sorafenib—Nausea—Docetaxel—ovarian cancer	4.98e-05	0.000276	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—ovarian cancer	4.97e-05	0.000276	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—ovarian cancer	4.91e-05	0.000273	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.88e-05	0.000271	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—ovarian cancer	4.87e-05	0.00027	CcSEcCtD
Sorafenib—Pain—Epirubicin—ovarian cancer	4.83e-05	0.000268	CcSEcCtD
Sorafenib—Constipation—Epirubicin—ovarian cancer	4.83e-05	0.000268	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.76e-05	0.000264	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—ovarian cancer	4.66e-05	0.000259	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—ovarian cancer	4.62e-05	0.000256	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—ovarian cancer	4.6e-05	0.000255	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—ovarian cancer	4.55e-05	0.000252	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.51e-05	0.000251	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—ovarian cancer	4.51e-05	0.00025	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—ovarian cancer	4.49e-05	0.000249	CcSEcCtD
Sorafenib—Pain—Doxorubicin—ovarian cancer	4.47e-05	0.000248	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—ovarian cancer	4.47e-05	0.000248	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—ovarian cancer	4.47e-05	0.000248	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—ovarian cancer	4.47e-05	0.000248	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.28e-05	0.000237	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—ovarian cancer	4.16e-05	0.000231	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—ovarian cancer	4.15e-05	0.000231	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—ovarian cancer	4.13e-05	0.000229	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—ovarian cancer	4.13e-05	0.000229	CcSEcCtD
Sorafenib—ABCB1—lymph node—ovarian cancer	4.09e-05	0.000312	CbGeAlD
Sorafenib—Asthenia—Epirubicin—ovarian cancer	4.05e-05	0.000225	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—ovarian cancer	4e-05	0.000222	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—ovarian cancer	3.87e-05	0.000215	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—ovarian cancer	3.85e-05	0.000214	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—ovarian cancer	3.75e-05	0.000208	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—ovarian cancer	3.74e-05	0.000207	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—ovarian cancer	3.7e-05	0.000205	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—ovarian cancer	3.59e-05	0.000199	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—ovarian cancer	3.58e-05	0.000199	CcSEcCtD
Sorafenib—Rash—Epirubicin—ovarian cancer	3.56e-05	0.000198	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—ovarian cancer	3.56e-05	0.000198	CcSEcCtD
Sorafenib—Headache—Epirubicin—ovarian cancer	3.54e-05	0.000197	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—ovarian cancer	3.46e-05	0.000192	CcSEcCtD
Sorafenib—Nausea—Epirubicin—ovarian cancer	3.36e-05	0.000186	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—ovarian cancer	3.32e-05	0.000185	CcSEcCtD
Sorafenib—Rash—Doxorubicin—ovarian cancer	3.3e-05	0.000183	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—ovarian cancer	3.29e-05	0.000183	CcSEcCtD
Sorafenib—Headache—Doxorubicin—ovarian cancer	3.28e-05	0.000182	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—ovarian cancer	3.11e-05	0.000172	CcSEcCtD
Sorafenib—FGFR1—Signaling Pathways—NRAS—ovarian cancer	1.73e-06	9.09e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—ovarian cancer	1.73e-06	9.09e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—ovarian cancer	1.73e-06	9.09e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.72e-06	9.08e-06	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—ovarian cancer	1.72e-06	9.08e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—ovarian cancer	1.72e-06	9.07e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—ovarian cancer	1.72e-06	9.06e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—ovarian cancer	1.72e-06	9.06e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—ovarian cancer	1.72e-06	9.06e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—ovarian cancer	1.72e-06	9.05e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—ovarian cancer	1.72e-06	9.04e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—ovarian cancer	1.72e-06	9.03e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—ovarian cancer	1.71e-06	9.01e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.71e-06	9e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—ovarian cancer	1.7e-06	8.96e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—ovarian cancer	1.7e-06	8.94e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—ovarian cancer	1.69e-06	8.92e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—ovarian cancer	1.69e-06	8.92e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—ovarian cancer	1.69e-06	8.92e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—ovarian cancer	1.69e-06	8.9e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—ovarian cancer	1.68e-06	8.87e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—ovarian cancer	1.68e-06	8.86e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—ovarian cancer	1.68e-06	8.84e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—ovarian cancer	1.68e-06	8.84e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—ovarian cancer	1.68e-06	8.83e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—ovarian cancer	1.67e-06	8.78e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAV1—ovarian cancer	1.66e-06	8.76e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—ovarian cancer	1.66e-06	8.73e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK1—ovarian cancer	1.66e-06	8.73e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK1—ovarian cancer	1.66e-06	8.73e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—ovarian cancer	1.66e-06	8.72e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—ovarian cancer	1.66e-06	8.72e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK3—ovarian cancer	1.65e-06	8.7e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—ovarian cancer	1.65e-06	8.68e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	1.65e-06	8.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—ovarian cancer	1.65e-06	8.67e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—ovarian cancer	1.64e-06	8.65e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—ovarian cancer	1.64e-06	8.63e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—ovarian cancer	1.62e-06	8.53e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—ovarian cancer	1.62e-06	8.52e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—ovarian cancer	1.62e-06	8.51e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—ovarian cancer	1.61e-06	8.46e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—ovarian cancer	1.6e-06	8.45e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	1.6e-06	8.44e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—ovarian cancer	1.6e-06	8.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	1.6e-06	8.41e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—ovarian cancer	1.59e-06	8.4e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—ovarian cancer	1.59e-06	8.38e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—ovarian cancer	1.59e-06	8.37e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.59e-06	8.37e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—ovarian cancer	1.59e-06	8.36e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—ovarian cancer	1.58e-06	8.32e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.57e-06	8.29e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CD—ovarian cancer	1.57e-06	8.28e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK1—ovarian cancer	1.57e-06	8.28e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—ovarian cancer	1.57e-06	8.28e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	1.57e-06	8.27e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	1.57e-06	8.26e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	1.57e-06	8.26e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	1.57e-06	8.26e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.57e-06	8.25e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—ovarian cancer	1.56e-06	8.24e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—ovarian cancer	1.56e-06	8.24e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—ovarian cancer	1.56e-06	8.24e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—ovarian cancer	1.56e-06	8.22e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—ovarian cancer	1.56e-06	8.21e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	8.19e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	1.55e-06	8.19e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	1.55e-06	8.17e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—ovarian cancer	1.55e-06	8.16e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—ovarian cancer	1.55e-06	8.16e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—ovarian cancer	1.55e-06	8.16e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MTOR—ovarian cancer	1.55e-06	8.15e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	1.55e-06	8.15e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—ovarian cancer	1.54e-06	8.12e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.54e-06	8.09e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—ovarian cancer	1.53e-06	8.05e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—ovarian cancer	1.51e-06	7.98e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.51e-06	7.98e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—ovarian cancer	1.51e-06	7.96e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—FASN—ovarian cancer	1.5e-06	7.92e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—ovarian cancer	1.5e-06	7.88e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—ovarian cancer	1.5e-06	7.88e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	1.49e-06	7.83e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—ovarian cancer	1.49e-06	7.82e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	1.48e-06	7.82e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAV1—ovarian cancer	1.48e-06	7.82e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—ovarian cancer	1.48e-06	7.81e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	1.48e-06	7.8e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.48e-06	7.79e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—ovarian cancer	1.48e-06	7.79e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	1.48e-06	7.78e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—ovarian cancer	1.48e-06	7.77e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—ovarian cancer	1.46e-06	7.7e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.46e-06	7.69e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	1.45e-06	7.65e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAV1—ovarian cancer	1.45e-06	7.63e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	1.44e-06	7.61e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—ovarian cancer	1.44e-06	7.6e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—ovarian cancer	1.44e-06	7.57e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	1.44e-06	7.57e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	1.44e-06	7.56e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—ovarian cancer	1.43e-06	7.56e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—ovarian cancer	1.43e-06	7.53e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.43e-06	7.52e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—ovarian cancer	1.42e-06	7.5e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—ovarian cancer	1.42e-06	7.48e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.42e-06	7.47e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK3—ovarian cancer	1.42e-06	7.46e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—ovarian cancer	1.41e-06	7.45e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	1.41e-06	7.44e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	1.41e-06	7.44e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—ovarian cancer	1.41e-06	7.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—ovarian cancer	1.4e-06	7.37e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—ovarian cancer	1.4e-06	7.37e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—ovarian cancer	1.39e-06	7.32e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—ovarian cancer	1.39e-06	7.32e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—ovarian cancer	1.39e-06	7.3e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—ovarian cancer	1.39e-06	7.3e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—ovarian cancer	1.38e-06	7.28e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—ovarian cancer	1.38e-06	7.28e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—ovarian cancer	1.38e-06	7.27e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—ovarian cancer	1.38e-06	7.25e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	1.37e-06	7.22e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.37e-06	7.22e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.37e-06	7.21e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAV1—ovarian cancer	1.36e-06	7.19e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—ovarian cancer	1.36e-06	7.19e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	1.36e-06	7.17e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAV1—ovarian cancer	1.35e-06	7.13e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.35e-06	7.12e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	1.35e-06	7.1e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—ovarian cancer	1.35e-06	7.09e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—ovarian cancer	1.34e-06	7.08e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—ovarian cancer	1.34e-06	7.07e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—ovarian cancer	1.34e-06	7.07e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.34e-06	7.06e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—ovarian cancer	1.34e-06	7.04e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	1.33e-06	7.03e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.33e-06	7.01e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—ovarian cancer	1.33e-06	7e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—ovarian cancer	1.33e-06	7e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK3—ovarian cancer	1.32e-06	6.97e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—ovarian cancer	1.32e-06	6.95e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.32e-06	6.95e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	1.32e-06	6.93e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	1.3e-06	6.87e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—ovarian cancer	1.3e-06	6.86e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.29e-06	6.81e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—ovarian cancer	1.29e-06	6.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—ovarian cancer	1.29e-06	6.78e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—ovarian cancer	1.27e-06	6.71e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—ovarian cancer	1.27e-06	6.7e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—ovarian cancer	1.27e-06	6.7e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—ovarian cancer	1.27e-06	6.7e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—ovarian cancer	1.26e-06	6.65e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK1—ovarian cancer	1.26e-06	6.63e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—ovarian cancer	1.26e-06	6.63e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	1.26e-06	6.63e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.24e-06	6.55e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.23e-06	6.49e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	1.23e-06	6.46e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.21e-06	6.4e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—ovarian cancer	1.21e-06	6.36e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.21e-06	6.36e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	1.21e-06	6.35e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.2e-06	6.3e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.19e-06	6.28e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—ovarian cancer	1.19e-06	6.26e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.19e-06	6.26e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	1.19e-06	6.25e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—ovarian cancer	1.18e-06	6.24e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—ovarian cancer	1.17e-06	6.18e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—ovarian cancer	1.17e-06	6.18e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	1.17e-06	6.16e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.16e-06	6.11e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.16e-06	6.11e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—ovarian cancer	1.16e-06	6.1e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAV1—ovarian cancer	1.16e-06	6.09e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.14e-06	6.02e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.14e-06	6e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	1.13e-06	5.97e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—ovarian cancer	1.13e-06	5.96e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—ovarian cancer	1.13e-06	5.95e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.13e-06	5.94e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—ovarian cancer	1.11e-06	5.87e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	1.11e-06	5.85e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.11e-06	5.85e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.11e-06	5.83e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.1e-06	5.82e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—ovarian cancer	1.1e-06	5.78e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—ovarian cancer	1.1e-06	5.78e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.09e-06	5.76e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—ovarian cancer	1.09e-06	5.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.09e-06	5.72e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.09e-06	5.72e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	1.09e-06	5.72e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.08e-06	5.71e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—ovarian cancer	1.08e-06	5.7e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—ovarian cancer	1.06e-06	5.57e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.05e-06	5.55e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.04e-06	5.45e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—ovarian cancer	1.04e-06	5.45e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.03e-06	5.41e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—ovarian cancer	1.01e-06	5.32e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.01e-06	5.32e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—ovarian cancer	1e-06	5.28e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	1e-06	5.27e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—ovarian cancer	9.68e-07	5.1e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—ovarian cancer	9.55e-07	5.03e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	9.53e-07	5.02e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CB—ovarian cancer	9.44e-07	4.97e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	9.43e-07	4.97e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—ovarian cancer	9.31e-07	4.9e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CD—ovarian cancer	9.26e-07	4.88e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—ovarian cancer	9.23e-07	4.86e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—ovarian cancer	9.13e-07	4.81e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—ovarian cancer	8.95e-07	4.71e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—ovarian cancer	8.93e-07	4.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAV1—ovarian cancer	8.92e-07	4.7e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—ovarian cancer	8.74e-07	4.6e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—ovarian cancer	8.73e-07	4.6e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—ovarian cancer	8.36e-07	4.4e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—ovarian cancer	8.35e-07	4.4e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—ovarian cancer	8.23e-07	4.34e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	8.17e-07	4.3e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—ovarian cancer	8.16e-07	4.3e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	8.13e-07	4.28e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CB—ovarian cancer	8.07e-07	4.25e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—ovarian cancer	7.71e-07	4.06e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	7.15e-07	3.76e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	7.07e-07	3.73e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—ovarian cancer	6.97e-07	3.67e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—ovarian cancer	6.83e-07	3.59e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—ovarian cancer	6.67e-07	3.51e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—ovarian cancer	6.31e-07	3.33e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	6.23e-07	3.28e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—ovarian cancer	6.16e-07	3.25e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.81e-07	3.06e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—ovarian cancer	5.78e-07	3.04e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—ovarian cancer	5.76e-07	3.03e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—ovarian cancer	5.38e-07	2.83e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—ovarian cancer	5.16e-07	2.72e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—ovarian cancer	5.03e-07	2.65e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—ovarian cancer	4.92e-07	2.59e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—ovarian cancer	4.74e-07	2.5e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—ovarian cancer	4.7e-07	2.48e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—ovarian cancer	4.02e-07	2.12e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.8e-07	2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—ovarian cancer	3.1e-07	1.63e-06	CbGpPWpGaD
